Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Subscribe To Our Newsletter & Stay Updated
